Monoclonal Antibody Treatment (Regen-COV)

Monoclonal Antibody Treatment (Regen-COV)

COVID-19 can be serious, even life-threatening. If you test positive for COVID-19, you’ll want to ask about monoclonal antibodies. This treatment is appropriate for people who test positive, have symptoms (must be less than 10 days from onset) and who have risk factors that leave them vulnerable to complications from the virus. These risk factors include asthma, high blood pressure, obesity, pregnancy, smoking (current or former) and many more. For a complete list of qualifications for monoclonal antibody treatment, see our FAQs below. Insurance is accepted for this treatment.

What are monoclonal antibodies?

Monoclonal antibodies are produced in a laboratory. They serve as substitute antibodies that help our immune systems mimic the defense of natural COVID-19 antibodies. Innovative Care uses the monoclonal antibody Regen-COV (casirivimab and imdevimab, administered together, made by Regeneron) to treat COVID positive patients. This treatment received FDA EUA approval in November, 2020 for patients who qualify, yet it is not yet widely available. Innovative Care is committed to fighting COVID and proud to offer a treatment for those who are fighting the virus. More information on Regen-COV can be found here

Treatment at Innovative COVID

Innovative COVID will be treating patients who qualify with monoclonal antibodies 5 days a week. Each visit begins with a physician consultation. If the patient opts to receive treatment, we will administer Regen-COV during the appointment. More information about what to expect can be found in the FAQs below. 

Insurance Accepted

Since we are the first private clinic giving monoclonal antibodies at a large scale, we have the ability to see what insurances have been paying. Innovative COVID accepts most major insurance plans, and 90 percent of people who get this treatment will not get a bill or pay for monoclonal antibody treatment. Five percent of patients will only pay a co-pay of $40 or less. And 5% will get a bill for around $350 for the medication infusion.If you do not have any medical insurance, your treatment will be covered under the federal CARES Act (no out of pocket cost to you).



Monoclonal Antibody Treatment FAQ

Anyone age 12 and older who tested positive for COVID-19 (whether they are vaccinated or not), and has had COVID-19 symptoms for less than 10 days, and who has one of the following:

  • Be at least 65 years old
  • Have a BMI of more than 25 kg/m2, or if age 12-17, have BMI above the 85th percentile for their age and gender based on CDC growth charts
  • Currently pregnant
  • Have a medical condition, including:
    • Cancer
    • High blood pressure
    • Chronic kidney disease
    • Cardiovascular disease (including congenital heart disease, hypertension)
    • Diabetes
    • Down syndrome
    • Dementia
    • Liver disease
    • Chronic lung disease
    • Sickle cell disease
    • Immunosuppressive disease or immunosuppressive treatment
  • Current or former smoker
  • History of stroke or cerebrovascular disease
  • Current or history of substance abuse
  • Neurodevelopmental disorders or other conditions that confer medical complexity
  • Have a medical-related technological dependence (e.g., tracheostomy, gastrostomy)

Note: Monoclonal antibody treatment needs to be given within 10 days of the start of symptoms. 

Monoclonal antibodies are administered via an IV infusion at our clinics. The appointment lasts about 90 minutes and begins with an evaluation from our emergency medicine physician or provider. Patients who schedule an appointment are under no obligation to have the infusion. They come for a consultation, at which time they can make a decision about whether or not to get monoclonal antibodies. If they choose to undergo treatment, we will administer the treatment during the same appointment. Treatment is administered in a comfortable recliner. Following your infusion, you will need to stay on-site for one hour for monitoring. 

After entering your body, monoclonal antibodies look for and attach to the spike protein that sticks out of the coronavirus that causes COVID-19. When monoclonal antibodies attach to the spike protein, they can block the virus’s ability to enter cells — and slow down the infection.

In 2020, the FDA authorized several different monoclonal antibodies to treat COVID-19. More information can be found in this patient fact sheet.

Translate »